Global Barbiturate Anticonvulsant Drugs Market Trends, Business Overview, Industry Growth and Forecast to 2022-2028

The global barbiturate anticonvulsant drugs market is anticipated to grow at a significant CAGR 5% during the forecast period (2022-2028). Barbiturates are central nervous system depressants. Barbiturates are chemical derivatives of barbituric acid. Epilepsy, sleeplessness, and status epilepticus are all treated with barbiturates. Barbiturates come in pill form and can be taken either orally or intravenously. Barbiturate medications work by increasing the activity of gamma-aminobutyric acid, one of the brain’s key neurotransmitters (GABA). GABA have a sedative impact on the brain of the consumer.

The global barbiturate anticonvulsant medicines market is growing due to an rising prevalence of seizures around the globe. According to Healthline Media and the Epilepsy Foundation of America, around 150,000 persons in the US are diagnosed with central nervous system illnesses that cause seizures each year. Additionally, the global barbiturate anticonvulsant drugs market is expected to be driven by the rising prevalence of insomnia. The most prevalent sleep issue is insomnia, which affects over one third of the global population. Furthermore, rising prevalence of epilepsy and anxiety in industrialized countries as a result of high work-related stress will raise the demand for barbiturate anticonvulsant drugs.

The market players are also contributing significantly in the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, in order to stay competitive in the market. For instance,

• In June 2021, Eisai Co., Ltd. announced its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched DAYVIGO (generic name: lemborexant), an orexin receptor antagonist discovered and developed in-house, for the treatment of adults with insomnia characterized by sleep onset and/or sleep maintenance difficulties.
• In July 2019, Ramelteon tablets, used to treat insomnia, were launched in the US market by Zydus Cadila. The USFDA has given final approval to Ramelteon tablets, 8 mg. Ramelteon is a hypnotic, that is a type of sedative.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Competitive Landscape- Teva Pharmaceutical Industries Ltd., Astellas Pharma Technologies Inc., GlaxoSmithKline plc, Valeant Pharmaceuticals, and Watson Laboratories, Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Barbiturate Anticonvulsant Drugs Market Report by Segment

By Type

• Ultra-Short Acting Barbiturate Anticonvulsant Drugs
• Short-Acting Barbiturate Anticonvulsant Drugs
• Long-Acting Barbiturate Anticonvulsant Drugs
• Combination Drugs

By Application

• Hospitals
• Clinics